Belcheva M M, Vogel Z, Ignatova E, Avidor-Reiss T, Zippel R, Levy R, Young E C, Barg J, Coscia C J
E. A. Doisy Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, Missouri 63104-1079, USA.
J Neurochem. 1998 Feb;70(2):635-45. doi: 10.1046/j.1471-4159.1998.70020635.x.
Although it is well-established that G protein-coupled receptor signaling systems can network with those of tyrosine kinase receptors by several mechanisms, the point(s) of convergence of the two pathways remains largely undelineated, particularly for opioids. Here we demonstrate that opioid agonists modulate the activity of the extracellular signal-regulated protein kinase (ERK) in African green monkey kidney COS-7 cells transiently cotransfected with mu-, delta-, or kappa-opioid receptors and ERK1- or ERK2-containing plasmids. Recombinant proteins in transfected cells were characterized by binding assay or immunoblotting. On treatment with corresponding mu- ([D-Ala2,Me-Phe4,Gly-ol5]enkephalin)-, delta- ([D-Pen2,D-Pen5]enkephalin)-, or kappa- (U69593)-selective opioid agonists, a dose-dependent, rapid stimulation of ERK1 and ERK2 activity was observed. This activation was inhibited by specific antagonists, suggesting the involvement of opioid receptors. Pretreatment of cells with pertussis toxin abolished ERK1 and ERK2 activation by agonists. Cotransfection of cells with dominant negative mutant N17-Ras or with a betagamma scavenger, CD8- beta-adrenergic receptor kinase-C, suppressed opioid stimulation of ERK1 and ERK2. When epidermal growth factor was used to activate ERK1, chronic (>2-h) opioid agonist treatment resulted in attenuation of the stimulation by the growth factor. This inhibition was blocked by the corresponding antagonists and CD8- beta-adrenergic receptor kinase-C cotransfection. These results suggest a mechanism involving Ras and betagamma subunits of Gi/o proteins in opioid agonist activation of ERK1 and ERK2, as well as opioid modulation of epidermal growth factor-induced ERK activity.
虽然G蛋白偶联受体信号系统可通过多种机制与酪氨酸激酶受体信号系统形成网络已得到充分证实,但两条途径的交汇点在很大程度上仍未明确,尤其是对于阿片类药物而言。在此我们证明,阿片类激动剂可调节非洲绿猴肾COS-7细胞中细胞外信号调节蛋白激酶(ERK)的活性,这些细胞被瞬时共转染了μ-、δ-或κ-阿片受体以及含ERK1或ERK2的质粒。通过结合试验或免疫印迹对转染细胞中的重组蛋白进行表征。在用相应的μ-([D-Ala2,Me-Phe4,Gly-ol5]脑啡肽)、δ-([D-Pen2,D-Pen5]脑啡肽)或κ-(U69593)选择性阿片激动剂处理后,观察到ERK1和ERK2活性呈剂量依赖性快速刺激。这种激活被特异性拮抗剂抑制,提示阿片受体参与其中。用百日咳毒素预处理细胞可消除激动剂对ERK1和ERK2的激活。将细胞与显性负性突变体N17-Ras或βγ清除剂CD8-β-肾上腺素能受体激酶-C共转染,可抑制阿片对ERK1和ERK2的刺激。当用表皮生长因子激活ERK1时,慢性(>2小时)阿片激动剂处理导致生长因子刺激减弱。这种抑制被相应拮抗剂和CD8-β-肾上腺素能受体激酶-C共转染所阻断。这些结果提示,在阿片激动剂激活ERK1和ERK2以及阿片对表皮生长因子诱导的ERK活性的调节中,存在一种涉及Gi/o蛋白的Ras和βγ亚基的机制。